166 - ATELIER CONJOINT ACQ-CCC: TRAITEMENT PERCUTANÉ DES VALVULOPATHIES: OU EN SOMMES-NOUS EN 2021

Friday, October 22, 2021

1:35 PM – 2:20 PM EDT

Location: Channel 4

Target Audience: Clinical cardiologists, Trainee (clinical), Community cardiologists

Co-Chair(s)

Benoit Daneault, MD

Interventional Cardiologist
Centre hospitalier universitaire de Sherbrooke
Université de Sherbrooke
Sherbrooke, Quebec, Canada
Geneviève Giraldeau, n/a

Cardiologist, Heart transplant and heart failure department, echocardiography department, infiltratives and inflammatory cardiomyopathy clinic
Montreal Heart Institute
University of Montreal
Montreal, Quebec, Canada

Presenter(s)

Anita Asgar, MD, MSc

Interventional Cardiologist
Montreal Heart Institute
Université de Montréal
Montréal, Quebec, Canada
Jean-Michel Paradis, MD

Interventional Cardiologist
Quebec Heart and Lung Institute
Laval University
Quebec, Quebec, Canada
Josep Rodès-Cabau

Interventional Cardiologist
Quebec Heart and Lung Institute
Laval University
Quebec, Quebec, Canada

Planning Committee Member(s)

Hélène Mayrand

Cardiologist
Université de Montréal
Laval, Quebec, Canada
Isabelle Nault, MD, FRCPC

Cardiologist Electrophysiologist
Institut Universitaire de Cardiologie Et de Pneumologie de Québec
Université Laval
Québec, Quebec, Canada
Amélie Paquin, MD, MSc

Fellow
CCS, CSE
Université Laval
Québec, Quebec, Canada

Learning Objectives:

At the conclusion of this session participants will be able to:

identifier les patients éligibles à un TAVI et connaître les résultats chez les populations jugées marginales ou non traditionnelles pour une approche percutanée;
Identify candidates for TAVR and learn about outcomes of TAVR in non-traditional populations (lower risk populations usually referred for surgical TAVR);
identifier les patients éligibles à un traitement percutané de l’insuffisance tricuspide. Connaître les différentes modalités de traitement percutané de l’insuffisance tricuspide, les défis techniques associés et leurs performances; et
identify candidates to a percutaneous treatment for tricuspid regurgitation. Know the different percutaneous treatment modalities, the technical challenges and their expected performance; and
connaître les indications pour une intervention mitrale percutanée mitrale et revoir les résultats et les issues cliniques après une telle intervention.
know the indications for a percutaneous mitral valve intervention and review the results and outcomes after such procedure.

Objectifs

1- Identifier les patients éligibles à un TAVI et connaître les résultats chez les populations jugées marginales ou non traditionnelles pour une approche percutanée.
Identify candidates for TAVR and learn about outcomes of TAVR in non-traditional populations (lower risk populations usually referred for surgical TAVR)
2- Identifier les patients éligibles à un traitement percutané de l’insuffisance tricuspide. Connaître les différentes modalités de traitement percutané de l’insuffisance tricuspide, les défis techniques associés et leurs performances.
Identify candidates to a percutaneous treatment for tricuspid regurgitation. Know the different percutaneous treatment modalities, the technical challenges and their expected performance.
3- Connaître les indications pour une intervention mitrale percutanée mitrale et revoir les résultats et les issues cliniques après une telle intervention.
Know the indications for a percutaneous mitral valve intervention and review the results and outcomes after such a procedure.

Description de l’atelier
Workshop description

This workshop is intended to be presented in French, as part of the partnership with CCS and ACQ.

This workshop will fulfill the learning needs of those seeking a comprehensive overview of percutaneous valvular procedures. Clinical scenarios like those addressed in this workshop are a frequent challenge to all involved in the clinical management of patients. This workshop will provide participants with a comprehensive and practical approach to patient selection, percutaneous aortic, mitral, and tricuspid valvular intervention, technical aspects of interest to the general cardiologist, and outcome after such procedure.

The ACQ CME committee planned this workshop. Members of this committee include community and academic cardiologists, interventional cardiologists, and cardiology residents from diverse practices and experiences across Quebec. The ACQ CME has developed an objective and balanced representation of the topic of
" Atelier conjoint ACQ-SCC: Traitement percutané de valvulopathies: où en sommes-nous en 2021? " that is completely free of third-party influence and/or support. Selected speakers from across Quebec are representative of the diversity in gender, generation, and practice.